Visit https://www.peervoice.com/XSX860 to view the entire programme with slides. After completing “Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care”, participants will be able to: Apply current guideline recommendations for timely testing and screening for alpha-1 antitrypsin deficiency (AATD) to facilitate early diagnosis and interventions; Identify best practices and practical strategies for the collaborative monitoring and management of patients with AATD; and Assess the phase 3 landscape of investigational therapies for the treatment of liver disease associated with AATD.

Visit https://www.peervoice.com/MGY860 to view the entire programme with slides. After completing “Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials”, participants will be able to: Compare the study designs and endpoints of pivotal phase 3 clinical trials in transthyretin amyloid cardiomyopathy (ATTR-CM); Identify the differences in baseline characteristics of study populations in key phase 3 trials in ATTR-CM and their impact on study outcomes; and Evaluate the clinical relevance and practical applicability of available study outcomes from pivotal trials in ATTR-CM.

Visit https://www.peervoice.com/VBS860 to view the entire programme with slides. After completing “Nicoletta Policek, PhD - When You Are Not an HIV Specialist But You Are Addressing Broader Healthcare Needs of Individuals With HIV: What Do You Need to Know?”, participants will be able to: Identify strategies to improve communication between people living with HIV (PWLH) and healthcare providers (HCPs), reduce HCP stigma, and build positive perceptions of health management by non-HIV specialist HCPs; and Propose key practical preventative steps for HIV-associated comorbidities.

Visit https://www.peervoice.com/KHV860 to view the entire programme with slides. After completing “Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making”, participants will be able to: Identify best practices to optimize the recognition and diagnosis of patients with transthyretin amyloidosis (ATTR), including those with ATTRv-PN and those with mixed phenotype ATTR; Evaluate current and emerging treatment options for hereditary ATTR with polyneuropathy (ATTRv-PN), including key differences between therapies with regards to clinical trial design, patient populations studied, available outcomes, and administration considerations; and Apply a comprehensive, patient-centered approach to management of patients with ATTR, including those with ATTRv-PN and those with mixed phenotype ATTR.

Visit https://www.peervoice.com/DRF860 to view the entire programme with slides. After completing “Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia”, participants will be able to: Recognize health risks associated with idiopathic hypersomnia; Differentiate idiopathic hypersomnia from other conditions that cause excessive daytime sleepiness (EDS); Explain how to establish a confirmatory diagnosis of idiopathic hypersomnia; and Propose effective, individualized, evidence-based management strategies for patients with idiopathic hypersomnia.

Visit https://www.peervoice.com/RHA860 to view the entire programme with slides. After completing “Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy”, participants will be able to: Describe the pathophysiology of narcolepsy in the context of cardiovascular (CV) effects; Differentiate between narcolepsy medications regarding their impact on CV risk factors; Identify medications used for common comorbidities associated with narcolepsy that have the potential to increase CV risk; and Propose strategies to manage CV risk in patients with narcolepsy.

Visit https://www.peervoice.com/ZFW860 to view the entire programme with slides. After completing “Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care”, participants will be able to: Summarise key data which informs guideline-driven interventions for patients with chronic obstructive pulmonary disease (COPD); Identify treatable traits which can guide need for non-pharmacologic interventions and selection of pharmacotherapy, including triple therapy, for patients with COPD; and Use patient- and disease-specific considerations and treatable traits to guide comprehensive management strategies for patients with COPD.

Visit https://www.peervoice.com/UWS860 to view the entire programme with slides. After completing “David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death”, participants will be able to: Recognise current unmet needs in the management of chronic obstructive pulmonary disease (COPD); Explain the rationale for early interventions, including both non-pharmacologic and pharmacologic, to improve control of symptoms and reduce exacerbations in patients with COPD; and Apply treatment guidelines for key non-pharmacologic and pharmacologic interventions in the management of patients with COPD.

Visit https://www.peervoice.com/UET860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023”, participants will be able to: Discuss emerging clinical data related to the management of hypertrophic cardiomyopathy (HCM); Describe the latest updates on guideline recommendations for provision of evidence-based care for patients with HCM; and Use emerging clinical data and latest updates on guideline recommendations to manage patients with HCM.

Visit https://www.peervoice.com/JHP860 to view the entire programme with slides. After completing “Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD”, participants will be able to: Identify current unmet needs in the achievement of goals of care in patients with chronic obstructive pulmonary disease (COPD); Describe the role of type 2 inflammation in the pathophysiology of COPD; and Evaluate emerging efficacy and safety data for the use of biologic therapies in the treatment of COPD.

Visit https://www.peervoice.com/HPG860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations”, participants will be able to:

Visit https://www.peervoice.com/THW860 to view the entire programme with slides. After completing “Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers”, participants will be able to: Identify unmet needs in the identification and diagnosis of patients with transthyretin amyloidosis (ATTR); and Apply recommended approaches to promote accurate and timely diagnosis and intervention in ATTR.

Visit https://www.peervoice.com/CFX860 to view the entire programme with slides. After completing “Michael Thorpy, MD - Dual Duty: Protecting Cardiovascular Health in Patients With Narcolepsy ”, participants will be able to: Explain the relationship between the pathophysiology of narcolepsy and cardiovascular (CV) risk; Identify contributors to CV risk in patients with narcolepsy; and Design practical approaches to reduce CV risk in patients receiving medications for narcolepsy.

Visit https://www.peervoice.com/GYJ860 to view the entire programme with slides. After completing “Franco Cecchi, MD - Improving Collaborative Care for HCM: Tips and Tricks From the Multidisciplinary Cardiology Team”, participants will be able to: Identify practical strategies to improve the timely diagnosis of hypertrophic cardiomyopathy (HCM) within their own practice and through facilitation of multidisciplinary care and referrals; Use effective strategies for selection of cardiac imaging techniques to improve diagnosis, assessment, and monitoring of patients with HCM; and Assess the potential role of novel pharmacologic and invasive treatments within the existing treatment paradigm for HCM.

Visit https://www.peervoice.com/AJZ860 to view the entire programme with slides. After completing “Payal Patel, MD, MPH - Rapid Diagnostic Testing: Getting the Upper Hand on Respiratory Tract Infections”, participants will be able to: Discuss the importance of rapid diagnostic testing for improving outcomes in patients with respiratory tract infections; Describe the link between rapid diagnostic testing, antimicrobial stewardship, and treatment decision-making; and Formulate optimal diagnostic testing plans for patients with respiratory tract infections.

Visit https://www.peervoice.com/ETY860 to view the entire programme with slides. After completing “Perry Elliott, MD, FRCP, FESC - Thickening of the Heart, and HCM Is to Blame: A Call for Improved Recognition, Diagnosis, and Management of HCM”, participants will be able to: Identify unmet needs in the recognition, diagnosis, and management of patients with hypertrophic cardiomyopathy (HCM); Assess the impact of HCM and its clinical manifestations and consequences on patient lives and quality of life; and Evaluate the potential role of novel technologies and therapies in the diagnosis and management of HCM.

Visit https://www.peervoice.com/AVQ860 to view the entire programme with slides. After completing “Ewa A. Jankowska, MD, PhD - Breakthroughs and Game-Changers in Heart Failure”, participants will be able to: Describe the pathophysiology of heart failure with reduced ejection fracture (HFrEF) and heart failure with preserved ejection fracture (HFpEF); Explain the rationale for SGLT2 inhibition in patients with HFrEF and HFpEF; and Discuss the potential clinical implications of novel strategies for ongoing support of patients with HFrEF and HFpEF.

Visit https://www.peervoice.com/URC860 to view the entire programme with slides. After completing “Wytske Fokkens, MD, PhD - Biologics for CRSwNP Management: Your Questions Answered”, participants will be able to: Evaluate how biologic therapies fit into the treatment paradigm for patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Use patient and disease characteristics to identify patients who may benefit from biologic therapy; and Apply practical strategies for monitoring and managing patients with CRSwNP who are receiving biologic therapy.

Visit https://www.peervoice.com/GXR860 to view the entire programme with slides. After completing “Javed Butler, MD, MPH, MBA - Changing the Patient Journey Across the Spectrum of Heart Failure”, participants will be able to: Recognise the different pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF); Summarise how SGLT2 inhibitors are changing the treatment paradigm for HFpEF and HFrEF; and Apply updated strategies to management of patients with HFpEF and HFrEF, with the goal of improving outcomes.

Visit https://www.peervoice.com/YZP860 to view the entire programme with slides. After completing “Evolving Clinical Management of the Hospitalised COVID-19 Patient”, participants will be able to: Summarise the biological processes that can manifest in a patient hospitalised due to COVID-19; Translate the current clinical data on antiviral therapies for patients hospitalised due to COVID-19 in the context of the evolving understanding of the disease processes that may be involved; and Identify patients hospitalised due to COVID-19 who are most likely to benefit from an antiviral therapy.